

Mesenchymal stem cells derived *in vitro* transdifferentiated insulin-producing cells: A new approach to treat type 1 diabetes

Shruti Dave

Department of Pathology, Laboratory Medicine, Transfusion Services and Immunohematology, Stem Cell Lab and Transplant Biology Research Centre, G. R. Doshi and K. M. Mehta Institute of Kidney Diseases and Research Centre-Dr. H. L. Trivedi Institute of Transplantation Sciences, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India

Abstract

The pathophysiology of type 1 diabetes mellitus (T1DM) is largely related to an innate defect in the immune system culminating in a loss of self-tolerance and destruction of the insulin-producing β -cells. Currently, there is no definitive cure for T1DM. Insulin injection does not mimic the precise regulation of β -cells on glucose homeostasis, leading long term to the development of complications. Stem cell therapy is a promising approach and specifically mesenchymal stem cells (MSCs) offer a promising possibility that deserves to be explored further. MSCs are multipotent, nonhematopoietic progenitors. They have been explored as an treatment option in tissue regeneration as well as potential of *in vitro* transdifferentiation into insulin-secreting cells. Thus, the major therapeutic goals for T1DM have been achieved in this way. The regenerative capabilities of MSCs have been a driving force to initiate studies testing their therapeutic effectiveness; their immunomodulatory properties have been equally exciting; which would appear capable of disabling immune dysregulation that leads to β -cell destruction in T1DM. Furthermore, MSCs can be cultured under specially defined conditions, their transdifferentiation can be directed toward the β -cell phenotype, and the formation of insulin-producing cells (IPCs) can be targeted. To date, the role of MSCs-derived IPC in T1DM—a unique approach with some positive findings—have been unexplored, but it is still in its very early phase. In this study, a new approach of MSCs-derived IPCs, as a potential therapeutic benefit for T1DM in experimental animal models as well as in humans has been summarized.

Key Words: Insulin-producing cells, mesenchymal stem cells, transdifferentiation, type 1 diabetes mellitus

Address for correspondence:

Dr. Shruti Dave, Department of Pathology, Laboratory Medicine, Transfusion Services and Immunohematology, Stem Cell Lab and Transplant Biology Research Centre, G. R. Doshi and K.M. Mehta Institute of Kidney Diseases and Research Centre (IKDRC)- Dr. H. L. Trivedi Institute of Transplantation Sciences (ITS), Civil Hospital Campus, Asarwa, Ahmedabad - 380 016, Gujarat, India. E-mail: shrutidave@yahoo.com

Received: 01-05-2013, **Accepted:** 21-07-2013

Access this article online	
Quick Response Code:	Website: www.advbiores.net
	DOI: 10.4103/2277-9175.148247

INTRODUCTION

Type 1 diabetes mellitus (T1DM) is a T-cell mediated, organ-specific autoimmune disorder leading to β -cell destruction and reduced insulin production and has no definitive cure currently. Standard treatment strategies for T1DM are based on different insulin replacements. However, as exogenous insulin cannot

Copyright: © 2013 Dave. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article: Dave S. Mesenchymal stem cells derived in vitro transdifferentiated insulin-producing cells: A new approach to treat type 1 diabetes. Adv Biomed Res 2014;3:266.

mimic exactly the physiology of insulin secretion, good metabolic control is difficult to reach and frequently associated with severe hypoglycemic episodes.^[1] At present, pancreas transplantation or islet transplantation as a treatment of T1DM is here to stay until something better comes along. The first efforts focused on whole pancreas transplants, which have been performed now for over 50 years. Although they have been shown to lead to insulin independence for several years, pancreas transplants to treat T1DM are not widespread for a number of reasons. Being a major surgery, the accompanying risk of mortality is 1-3% and the complications that ensue include cardiac death and systemic infections. In addition, to prevent the body from rejecting the transplanted pancreas, recipients must take powerful immunosuppressions for the rest of their lives, leaving them susceptible to infections and a range of other diseases. Many feel that the immunosuppressions therapy could be a greater health threat than the diabetes itself.^[2]

In an effort to more tightly control blood glucose levels, researchers began to explore the possibilities of using cell-based therapies that would replace lost β -cells. Within recent years, stem cell research has become a very important part of the scientific understanding of T1DM. Research has demonstrated that stem cells can be grown in the lab and could lead to a better availability of β -cells for future research purposes to treat T1DM. Many types of stem cells are candidates for the treatment of T1DM.^[3] The ideal stem cells would be the one with strong immunomodulatory and regenerative properties which would have to deal with active process of autoimmunity that probably target the newly formed insulin-producing cells (IPCs). Mesenchymal stem cells (MSCs) have been a driving force to initiate studies testing their therapeutic effectiveness with their regenerative capabilities and their immunomodulatory properties. Generation of IPCs from MSCs represents an attractive alternative.^[2] Although the sources of stem cells used in the generation of IPC have been previously reviewed, the literature describing MSCs alone as a source for *in vitro* transdifferentiation of IPC, further clinical use of IPC as a therapeutic agent in experimental animal models and in humans, and its outcome are limited, which encourage the author to carry out this review.

REVIEW

Mesenchymal stem cells therapeutic potential: *In vitro* and *in vivo* evidence

Friedenstein *et al.*, in a ground-breaking study, isolated clonogenic fibroblast precursor cells from whole bone marrow (BM) and showed that they were

capable of forming bone- and cartilage-like colonies.^[4] Since then BM-derived stem cells are still the most frequently investigated cell type and often designated as the gold standard. Till date isolation of multipotent MSCs from different sources has been reported. There is no universally agreed upon set or a specific singular marker to identify these cells. As a result, a battery of negative and positive markers is generally used to phenotypically characterize these cells. As MSCs are a nonhematopoietic cell lineage, they generally lack specific cell surface markers of HSC and do not express hematopoietic markers such as CD34, CD14 and CD45, CD11a/LFA-1, erythrocytes (glycophorin A), and platelet and endothelial cell adhesion molecules (CD31), but they express several other cell surface antigens, such as CD73 (SH3/4), CD90, CD105 (SH2), CD146, and CD200. They also express variable levels of CD44, stromal antigen 1, and a group of other adhesion molecules and receptors including CD166 (vascular cell adhesion molecule), CD54/CD102 (intracellular adhesion molecule), and CD49.^[5] BM aspirate is considered to be the most accessible and enriched source of MSCs. Bone marrow-derived MSCs (BM-MSCs) represent a rare population of cells that make up only 0.001-0.01% of total nucleated cells and are 10-fold less abundant than hematopoietic stem cells (HSCs), but they can be readily grown and expanded in culture.^[6] However, MSCs derived from adipose tissue (AD-MSCs),^[7,8] peripheral blood,^[9,10] and umbilical cord blood (UCB)^[11-13] have also shown promising potential for proliferation and differentiation into different cell types including IPCs. Moreover, protein transduction technology also offers a novel approach for generating IPCs from stem cells including MSCs.^[14,15]

Why MSC?

The frequency of T1DM has been steadily increasing worldwide and T1DM prevention studies using immunosuppressants, self-antigens, and dietary interventions have demonstrated largely disappointing results.^[1] In T1DM, selective and irreversible destruction of the insulin-secreting β -cells in the pancreatic islets of Langerhans occurs by an autoimmune attack. While insulin replacement remains the cornerstone treatment for T1DM, the transplantation of pancreatic islets of Langerhans provides a cure for this disorder and yet, islet transplantation is limited by the lack of donor pancreas. The challenge involves the development of safe and effective means affording the prevention or reversal of T1DM. MSCs have the capacity to differentiate into multiple mesodermal and nonmesodermal cell lineages including IPCs *in vitro*.^[2] MSCs that have been precommitted to one mesenchyme cell lineage can differentiate into

other cell types in response to inductive extracellular cues by process known as transdifferentiation. These precommitted cells proliferate and are able to dedifferentiate into a primitive stem cell stage through genome reprogramming.^[3] On the one hand, MSCs have the potential to transdifferentiate into IPCs by genetic modification and/or defined culture conditions *in vitro*. On the other hand, MSCs are able to serve as a cellular vehicle for the expression of human insulin gene and has a promising role as therapeutic agents in the treatment, the complications of DM such as cardiac function and in treatment of diabetic cardiomyopathy, nephropathy, diabetic polyneuropathy, and wounds in diabetic patients.^[16-22] MSCs have generated marked interest and attention for their capacity to elicit tissue regeneration^[6,23-25] and one of the most remarkable and least understood findings is the ability of MSC to migrate to sites of tissue injury.^[26-29] Besides, MSCs also possess immunosuppressive effects by modulating the immune function of the major cell populations involved in alloantigen recognition and elimination^[30-32] and they have also shown promising results in the treatment of other autoimmune disorders (e.g., experimental autoimmune encephalomyelitis and rheumatoid arthritis).^[33,34] Adult human MSCs express intermediate levels of major histocompatibility complex (MHC) class I molecules on their cell surface, but not MHC class II, properties that allow their transplantation across MHC barriers. Because of the lack in expression of MHC class II and most of the classical costimulatory molecules on MSCs, these cells have historically been regarded as hypoimmunogenic cells. The immunomodulatory properties of MSCs were initially reported in T-cell proliferation assays using one of a variety of stimuli including mitogens, CD3/CD28, and alloantigen settings where the ability of MSCs to suppress T-cell proliferation was readily determined. Such suppression occurs irrespective of a donor source, including settings in which one uses “third-party” MSCs and suppress proliferation of both CD4+ and CD8+ lymphocytes; and are able to abrogate the response of memory T-cells and naïve T cells to their antigen.^[35] MSCs could regulate diabetes through a direct effect by presenting differential levels of negative costimulatory molecules and secreting regulatory cytokines such as transforming growth factor- β and IL-10 that control regulatory T-cells/auto-reactive T-cells. It is also possible that MSCs could correct the dysregulation observed at the level of B-cells and natural killer cells as well.^[36-39] MSCs also exert antiinflammatory effects that could be important in maintaining peripheral tolerance.^[40-42] It has been shown that AD-MSCs are capable of producing anti-inflammatory cytokines and

angiogenic factors, which could potentially improve the diabetes-associated inflammatory and ischemic conditions.^[2] According to one hypothesis, MSC transplantation into diabetic animals can prevent apoptosis of injured pancreatic β -cells and enhance regeneration of endogenous progenitor cells through paracrine actions such as angiogenic, cytoprotective, anti-inflammatory, mitogenic, and antiapoptotic effects.^[43] MSCs have been also shown to provide cytokine and growth factor support for expansion of HSCs and human embryonic stem cells (ESCs), which in turn during cotransplantation of IPCs and HSCs promote IPC engraftment and survival. Here HSCs act as “feeder” cells for the IPCs, supporting its protection, tissue revascularization, and immune acceptance.^[25,44-46]

***In vitro* directed transdifferentiation of mscs into IPCs**

Assady *et al.* (2001) reported that IPCs can be generated from spontaneous differentiation using ESCs. Although the number of IPCs and the insulin content in these cells was low, it was the first proof-of-principle experiment showing that stem cells-ESCs were a potential source for generating β -like cells.^[47]

MSCs have the advantage over ESCs in that they usually do not form teratomas and are free from the ethical issues of ESCs. MSCs can be easily obtained and are easily expanded and cultured in the laboratory. Different types of stem cells require different culture and induction media for transdifferentiation of IPCs to take place. The capacity of MSCs to undergo functional transdifferentiation has been questioned over the years. Nonetheless, recent studies support that gene-therapy or factor-based transdifferentiation of MSCs are two distinctive pathways to be considered as means of obtaining functional β -cells. Gene-therapy refers to the *in vivo* or *in vitro* transfer of a foreign gene into MSCs, allowing it to produce insulin. The foreign gene in turn activates or represses on demand the insulin gene. The factor-based approach involves exposing MSCs to a cocktail of insulin-promoting factors and cytokines over an extended period of *in vitro* culture, followed by transplantation of the transdifferentiated IPC into the receiving diabetic patient.

MSCs can be differentiated into IPCs by using a specific culture medium enriched with extrinsic insulin-promoting factors. The IPC transdifferentiation period varies greatly with the use of different protocols, it may last from several days to several months. Addition and withdrawal of a combination of extrinsic insulin-promoting factors in a stage-wise manner are required. Many extrinsic insulin-promoting factors,

which are biologically active compounds, that have been used in endocrine pancreas differentiation have been shown to promote β -cell proliferation and differentiation and increase insulin content of IPC. A number of these factors have been commonly observed in protocols for IPC transdifferentiation. Different types of stem cells require different culture and induction media for differentiation of IPCs to take place. However, some common themes seem to appear in various induction methods. Commonly known insulin-promoting factors include epidermal growth factor, activin A, betacellulin, nicotinamide, exendin-4, hepatocyte growth factor, fibroblast growth factors, and pentagastrin. Careful use of serum and glucose in the induction media has also been indicated for successful transdifferentiation of IPCs. Signaling by these factors in MSCs allows the induction of the transcription factors, which are prerequisites for pancreas development [Table 1].

IPC identification is then based on the ability to express genes related to pancreatic development and function, such as *Isl1* and *Isl3*, *GLUT2*, glucose kinase, islet amyloid polypeptide, nestin, and *Pdx 1* and *Pax 6*, and to synthesize C-peptide and insulin, which have been shown to play a role in the development of the pancreas and/or the differentiation of insulin-producing β -cells. Although pancreas development has been partly deciphered by identification and characterization of many transcription factors little is known about their function and molecular mechanism of action. Most of these transcription factors are sequentially and transiently expressed during pancreas development. However, for successful transdifferentiation of MSCs into IPCs the *in vitro* culture procedure should follow at least the major part of transcriptional program.

There are evidence to suggest that pancreatic stem or progenitor cells derived MSCs.^[48-54] UCB derived MSCs,^[13,55,56] BM-MSCs,^[57-63] and AD-MSC^[52,64-66] can be isolated from rodents and/or human and extensively expanded *in vitro*, where they differentiate to form new IPCs and exhibited with the characteristics genes and a panel of markers considered essential for differentiation into pancreatic endocrine tissue (*Isl1*, *Pdx 1*, *Pax 4*, and *Ngn3*, *Pax 6*) [Table 2].

The majority of researchers have described a multistep protocol for generation of insulin-producing islet-like clusters from MSCs derived from different sources. The glucose challenge tests revealed the production of insulin, and such production was regulated through physiological signaling pathways, i.e. in a glucose responsible manner and they believed that IPCs

derived from MSCs could be potentially used for cell therapy of T1DM in human models followed by trials in experimental animal models [Figure 1].

Success story: MSCs derived IPCs-based therapy in autoimmune animal models of T1DM

Experimental data for the therapeutic effects of MSCs-derived IPCs in animal models of T1DM are important tools for analyzing results before considering further human clinical applications.

Table 1: Extrinsic factors and their role in promoting IPC differentiation and insulin production

Extrinsic factors	Role
Nutrients and other factors	
High glucose	Increases β -cell replication and hypertrophy besides neogenesis
Amino acids	Indirectly affect β -cell proliferation through
N2 and B27 serum supplements	Acts as a serum supplement in serum-free mediums
Nicotinamide	Associated with the development of β -cell outgrowths from undifferentiated epithelial cell clusters
Growth factors, cytokines and hormones	
Activin A and betacellulin	Promotes β -cell regeneration by increasing β -cell mass
Epidermal growth factor	Accelerates high degree of B-cell proliferation and high degree differentiation
Pentagastrin	Markedly expands β -cell mass, specifically when it is combined with other factors
Glucagon-like peptide-1 and exendin 4	Accelerates functional maturation of fetal β -cells as evidenced by their glucose-stimulated insulin secretion
Hepatocyte growth factor	Functions as an insulinotropic factor

IPC: Insulin-producing cells

Table 2: *In vitro* approaches to generate IPCs from different MSC sources

MSC source	Characteristics	References
Pancreatic MSC	Expression of <i>Pdx1</i> , <i>Hlx9</i> , <i>Nkx2.2</i> , <i>Nkx6.1</i> , and <i>GLUT2</i> . Released insulin and C-peptide in response to physiological glucose concentrations <i>in vitro</i> .	[48-54]
Human UCB-MSCs	Expression of <i>Isl1</i> , <i>Pdx1</i> , <i>Pax4</i> , and <i>Ngn3</i>	[3, 55, 56]
BM-MSCs	Generation of islet-like cells, expression of <i>PDX1</i>	[57-63]
ADSC-MSCs	Upregulation of transcription factors <i>lpf1</i> , <i>Isl1</i> , and <i>Ngn3</i> and islet gene insulin, glucagon and somatostatin, as well as expression of C-peptide	[64-66]

MSC: Mesenchymal stem cells

NOD/SCID mice, which are severely deficient in T and B lymphocytes, represent an invaluable diabetic model for experimental research. Use of IPCs derived from UCB-MSCs,^[56,67,68] BM-MSCs alone or in association with HSCs,^[18,59,69-71] and from AD-MSC^[72-75] represent a potential source of diabetic cell replacement. AD-MSCs because of their availability, low risk for immune rejection and increased capacity for expansion with encouraging results in terms of improving glycaemia, enhanced islet regeneration, lowered blood sugar and increased circulating blood insulin levels, increased production of endogenous β -cells, reversion of glycosuria, with increased morphologically normal β -pancreatic islets, acquired functional β -cell phenotype, partially restored pancreatic function in comparison with nontransplanted diabetic mice. Histological examination of IPCs transplanted organ showed the presence of transplanted cells with formation of tissue-like structure, which stained positive for insulin [Table 3].

MSCs or MSCs derived IPC-based therapy in T1DM humans

The most effective protocols till date have produced cells that express insulin and have molecular

characteristics that closely resemble bonafide IPC; however, these cells are often unresponsive to glucose, which is also a most vital characteristic concern that needs to be solved before finding a definite clinical application. There are very few reports noted till now using MSCs-derived IPC as a treatment of T1DM in humans. In 2008, researchers studied the role of MSCs in humans with T1DM. The protocol includes BM biopsy under general anesthesia in the first-degree relatives for the collection of MSC. These cells were sent to a laboratory to be stimulated to proliferate for a month and were later infused into the patient through a gelatinous solution of approximately 100 mL without chemotherapy. After 1 month, the patients were given another infusion. So far, they are not sure about how many infusions will be necessary. Two patients had been included in this protocol but still results are not published.^[76]

In the same year, in 2008, Trivedi *et al.* published results using AD-MSCs transdifferentiated IPCs in combination with HSCs to treat T1DM in five patients having disease duration of 0.6-10 years. Intraportal administration of *in vitro* generated IPCs and HSCs were carried out. We decided to infuse the cells in portal circulation since liver is the most tolerogenic organ.^[77] The results showed 30% to 50% decreased insulin requirements with 4 to 26-fold increased serum c-peptide levels, with a mean follow-up of 2.9 months without any untoward effects and without use of any immunosuppression.^[78]

In 2010, again vanikar *et al.* published results of insulin replacement therapy using AD-MSCs-derived IPC in combination with HSCs to treat T1DM in another 11 patients having disease duration of 1-24 years. Cells were administered intraportally. *In vitro* generated IPCs showed the presence of pancreatic transcriptional factors *Pax 6*, *Isl1*, and *Pdx 1* (by immunofluorescence assay). Chemiluminescence assay detected secretion of glucose and C-peptide in response to glucose concentration *in vitro*. Over a mean follow-up of 23 months, treated patients




Figure 1: Schematic representation showing *in vitro* transdifferentiation of insulin-producing cells from mesenchymal stem cells; IPC *in vivo* infusion in an experimental animal model, T1DM human model, and therapeutic effect

Table 3: Approaches to treat experimental diabetic model using IPCs generated from different MSC sources

MSC source	Animal model	Infusion procedure	Therapeutic effect	References
UCB-MSCs	NOD/SCID mice	Intravenous/implantation in the subcapsular region of kidney	Improved blood glucose levels and survival rates, led to normalization of glomerular hypertrophy and tubular dilatation	[56, 67, 68]
BM-MSCs	NOD/SCID mice	Intraportal/Intravenous injection	Reversion of hyperglycemia and glycosuria, improved renal lesions, increased circulating insulin and decreased inflammatory macrophage infiltrates in glomerular structures	[18, 59, 69-71]
ADSC-MSC	NOD/SCID mice	Intravenous/intraperitoneal injection	C-peptide decreased, Reversion of hyperglycemia and glycosuria	[72-75]

IPC: Insulin-producing cells

Table 4: Insulin replacement therapy using MSC-derived IPCs in humans

MSC source; year	Number of patients	Infusion procedure	Therapeutic effect	References
BM-MSC; 2008	N=2	Intravenous	Data not published	[76]
ADSC-MSC; 2008	N=5	Intraportal	Mean follow-up 2.9 months. Decreased exogenous insulin requirement, Hb1Ac, raised serum c-peptide levels, no immunosuppression	[77]
ADSC-MSC; 2010	N=11	Intraportal	Mean follow-up of 23 months. Decreased exogenous insulin requirement, Hb1Ac, raised serum c-peptide levels, and no diabetic ketoacidosis events, weight gain, no any immunosuppression	[78]

MSC: Mesenchymal stem cells, IPC: Insulin-producing cells




Figure 2: MSC transdifferentiation into IPC and its use in clinic learning points

showed a decreased mean exogenous insulin requirement, Hb1Ac, raised serum c-peptide levels, and became free of diabetic ketoacidosis events with weight gain on normal diet and physical activities without any untoward effects, without use of any immunosuppression^[79] [Table 4].

CONCLUSIONS AND FUTURE PERSPECTIVES

Taken altogether, these *in vitro* and *in vivo* experiments demonstrate that the beneficial effects of MSCs in T1DM may be related to both their immunosuppressant activity and subsequent protective effects on damaged tissue, and their capacity to transdifferentiate into IPCs [Figure 2].

With sporadic reports of use of MSCs-derived IPCs and their further use in clinical trials to treat T1DM, it can be concluded that (i) this study is only a first step toward using MSCs-derived IPCs as a cell-based treatment, which appears to be suitable for treatment of for T1DM, (ii) MSCs-derived IPCs are an ideal population of personal stem cells for cell replacement therapy and also MSCs could be induced to differentiate into physiologically competent functional islet-like

cell aggregates, which may provide as a source of alternative islets for cell replacement therapy in T1DM. Generation of MSCs into IPCs is feasible and promising making the transplantation of IPC a promising approach for the treatment of T1DM. However, there is no standard method for IPC generation and the wide variations in induction techniques used may be a challenge to researchers. As most of these stem cells are being tested in preclinical T1DM with rare clinical use in humans, further exploration is necessary for the *in vitro* generation of sufficient IPCs that can produce sufficient insulin for wide clinical use. The biggest challenge for the future trials using this approach is to prevent or treat relapses and maintain complete or very good partial responses for very long time.

REFERENCES

- Schatz D, Gale EA, Atkinson MA. Why can't we prevent type 1 diabetes? Maybe it's time to try a different combination. *Diabetes Care* 2003;26:3326-8.
- Liu M, Han ZC. Mesenchymal stem cells: Biology and clinical potential in type 1 diabetes therapy. *J Cell Mol Med* 2008;12:1155-68.
- Song L, Tuan RS. Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow. *FASEB J* 2004;18:980-2.
- Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. *Exp Hematol* 1976;4:267-4.
- Delorme B, Ringe J, Gallay N, Le Vern Y, Kerboeuf D, Jorgensen C, *et al.* Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells. *Blood* 2008;111:2631-5.
- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, *et al.* Multilineage potential of adult human mesenchymal stem cells. *Science* 1999;284:143-7.
- Fraser J, Wulur I, Alfonso Z, Hedrick M. Fat tissue: An underappreciated source of stem cells for biotechnology. *Trends Biotechnol* 2006;24:150-4.
- Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, *et al.* Multilineage cells from human adipose tissue: Implications for cell-based therapies. *Tissue Eng* 2001;7:211-28.
- Cao C, Dong Y. Study on culture and *in vitro* osteogenesis of blood-derived human mesenchymal stem cells. *Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi* 2005;19:642-7.
- Zvaifler NJ, Marinova-Mutafchieva L, Adams G, Edwards CJ, Moss J, Burger JA, *et al.* Mesenchymal precursor cells in the blood of normal individuals. *Arthritis Res* 2000;2:477-88.
- Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, *et al.* Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. *Haematologica* 2006;91:1017-26.

12. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. *Stem Cells* 2006;24:1294-301.
13. Pessina A, Eletti B, Croera C, Savalli N, Diodovich C, Gribaldo L. Pancreas developing markers expressed on human mononucleated umbilical cord blood cells: *Biochem Biophys Res Commun* 2004;323:315-22.
14. Vija L, Farge D, Gautier JF, Vexiau P, Dumitrache C, Bourgarit A, *et al.* Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes. *Diabetes Metab* 2009;35:85-93.
15. Davani B, Ariely S, Ikonomou L, Oron Y, Gerhengon M. Human islet derived cells can cycle between epithelial clusters and mesenchymal phenotypes. *J Cell Mol Med* 2009;13:2570-6.
16. Zhang N, Li J, Luo R, Jiang J, Wang JA. Bone marrow mesenchymal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy. *Exp Clin Endocrinol Diabetes* 2008;116:104-11.
17. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yañez AJ, Conget PA. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. *Biol Blood Marrow Transplant* 2008;14:631-40.
18. Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, *et al.* Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. *Proc Natl Acad Sci USA* 2006;103:17438-43.
19. Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. *Int J Mol Med* 2004;14:1035-41.
20. Yang Z, Li K, Yan X, Dong F, Zhao C. Amelioration of diabetic retinopathy by engrafted human adipose-derived mesenchymal stem cells in streptozotocin diabetic rats. *Graefes Arch Clin Exp Ophthalmol* 2010;248:1415-22.
21. Kwon DS, Gao X, Liu YB, Dulchavsky DS, Danyluk AL, Bansal M, *et al.* Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. *Int Wound J* 2008;5:453-63.
22. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. *Stem Cells* 2007;25:2648-59.
23. Caplan A, Dennis J. Mesenchymal stem cells as trophic mediators. *J Cell Biochem* 2006;98:1076-84.
24. Zhang Y, Li C, Jiang X, Zhang S, Wu Y, Liu B, *et al.* Human placenta-derived mesenchymal progenitor cells support culture expansion of long-term culture-initiating cells from cord blood CD34+ cells. *Exp Hematol* 2004;32:657-64.
25. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. *J Hematother Stem Cell Res* 2000;9:841-8.
26. Pittenger M, Martin B. Mesenchymal stem cells and their potential as cardiac therapeutics. *Circ Res* 2004;95:9-20.
27. Bittira B, Shum-Tim D, Al-Khaldi A, Chiu R. Mobilization and homing of bone marrow stromal cells in myocardial infarction. *Eur J Cardiothorac Surg* 2003;24:393-8.
28. Mackenzie T, Flake A. Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep. *Blood Cells Mol Dis* 2001;27:1-4.
29. Wu GD, Nolte JA, Jin YS, Barr ML, Yu H, Starnes VA, *et al.* Migration of mesenchymal stem cells to heart allografts during chronic rejection. *Transplantation* 2003;75:679-85.
30. Tse W, Pendleton J, Beyer W, Egalka M, Guinan E. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. *Transplantation* 2003;75:389-97.
31. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, *et al.* Human mesenchymal stem cells modulate B-cell functions. *Blood* 2006;107:367-72.
32. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, *et al.* Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+regulatory T cells. *Stem Cells* 2008;26:212-22.
33. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, *et al.* Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. *Blood* 2005;106:1755-61.
34. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, *et al.* Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. *Proc Natl Acad Sci U S A* 2007;104:11002-7.
35. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. *Scand J Immunol* 2003;157:11-20.
36. Rasmuson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. *Transplantation* 2003;76:1208-13.
37. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, *et al.* Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. *Stem Cells* 2006;24:386-98.
38. Poggi A, Prevosto C, Massaro AM, Negrini S, Urbani S, Pierri I, *et al.* Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: Role of NKP30 and NKG2D receptors. *J Immunol* 2005;175:6352-60.
39. Spaggiari G, Capobianco A, Abdelrazik H, Becchetti F, Mingari M, Moretta L. Mesenchymal stem cells inhibit natural killer cell proliferation, cytotoxicity and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. *Blood* 2008;111:1327-33.
40. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, *et al.* T cell responses to allogeneic human mesenchymal stem cells: Immunogenicity, tolerance, and suppression. *J Biomed Sci* 2005;12:47-57.
41. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. *J Intern Med* 2007;262:509-25.
42. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. *Exp Hematol* 2003;31:890-6.
43. Xu YX, Chen L, Wang R, Hou WK, Lin P, Sun L, *et al.* Mesenchymal stem cell therapy for diabetes through paracrine mechanisms. *Med Hypotheses* 2008;71:390-3.
44. Haynesworth S, Baber M, Caplan A. Cytokine expression by human marrow-derived mesenchymal progenitor cells *in vitro*: Effects of dexamethasone and IL-1 alpha. *J Cell Physiol* 1996;166:585-92.
45. Cheng L, Qasba P, Vanguri P, Thiede M. Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34+hematopoietic progenitor cells. *J Cell Physiol* 2000;184:58-69.
46. Cheng L, Hammond H, Ye Z, Zhan X, Dravid G. Human adult marrow cells support prolonged expansion of human embryonic stem cells in culture. *Stem Cells* 2003;21:131-42.
47. Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki KL, Tzukerman M. Insulin production by human embryonic stem cells. *Diabetes* 2001;50:1691-7.
48. Ramiya V, Maraist M, Arfors K, Schatz D, Peck A, Cornelius J. Reversal of insulin-dependent diabetes using islets generated *in vitro* from pancreatic stem cells. *Nat Med* 2000;6:278-82.
49. Lü P, Liu F, Yan L, Peng T, Liu T, Yao Z, *et al.* Stem cells therapy for type 1 diabetes. *Diabetes Res Clin Pract* 2007;78:1-7.
50. Seeberger K, Dufour J, Shapiro A, Lakey J, Rajotte R, Korbitt G. Expansion of mesenchymal stem cells from human pancreatic ductal epithelium. *Lab Invest* 2006;86:141-53.
51. Gershengorn MC, Hardikar AA, Wei C, Geras-Raaka E, Marcus-Samuels B, Raaka BM. Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. *Science* 2004;306:2261-4.
52. Timper K, Seboek D, Eberhardt M, Linscheid P, Christ-Crain M, Keller U, *et al.* Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagons-expressing cells. *Biochem Biophys Res Commun* 2006;341:1135-40.
53. Eberhardt M, Salmon P, von Mach MA, Hengstler JG, Brulport M,

Dave: Insulin producing cells for T1DM

- Linscheid P, *et al.* Multipotential nestin and Isl-1 positive mesenchymal stem cells isolated from human pancreatic islets. *Biochem Biophys Res Commun* 2006;345:1167-76.
54. Chou Y, Khoun S, Hermann H, Goldman R. Nestin promotes the phosphorylation-dependent disassembly of vimentin intermediate filaments during mitosis. *Mol Biol Cell* 2003;14:1468-78.
55. Hu YH, Wu DQ, Gao F, Li GD, Yao L, Zhang XC. A secretory function of human insulin-producing cells *in vivo*. *Hepatobiliary Pancreat Dis Int* 2009;8:255-60.
56. Chao KC, Chao KF, Fu YS, Liu SH. Islet-like clusters derived from mesenchymal stem cells in Wharton's jelly of the human umbilical cord for transplantation to control type 1 diabetes. *PLoS One* 2008;3:e1451.
57. Oh S, Muzzonigro T, Bae S, LaPlante J, Hatch H, Petersen B. Adult bone marrow-derived cells trans-differentiating into insulin-producing cells for treatment of type I diabetes. *Lab Invest* 2004;84:607-17.
58. Chen L, Jiang X, Yang L. Differentiation of rat marrow mesenchymal stem cells into pancreatic islet beta cells. *World J Gastroenterol* 2004;10:3016-20.
59. Wu XH, Liu CP, Xu KF, Mao XD, Zhu J, Jiang JJ, *et al.* Reversal of hyperglycaemia in diabetic rats by portal vein transplantation of islet-like cells generated from bone marrow mesenchymal stem cells. *World J Gastroenterol* 2007;13:3342-9.
60. Sun Y, Chen L, Hou XG, Hou WK, Dong JJ, Sun L, *et al.* Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells *in vitro*. *Chin Med J (Engl)* 2007;120:771-6.
61. Karnieli O, Izhar-Prato Y, Bulvik S, Efrat S. Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation. *Stem Cells* 2007;25:2837-44.
62. Tang DQ, Cao LZ, Burkhardt BR, Xia CQ, Litherland SA, Atkinson MA, *et al.* *In vivo* and *in vitro* characterization of insulin-producing cells obtained from murine bone marrow. *Diabetes* 2004;53:1721-32.
63. lanus A, Holz G, Theise N, Hussain M. *In vivo* derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. *J Clin Invest* 2003;111:843-50.
64. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, *et al.* Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell* 2002;13:4279-95.
65. Okura H, Komoda H, Fumimoto Y, Lee CM, Nishida T, Sawa Y, *et al.* Transdifferentiation of human adipose tissue-derived stromal cells into insulin-producing clusters. *J Artif Organs* 2009;12:123-30.
66. Dave SD, Vanikar AV, Trivedi HL. *Ex vivo* generation of glucose sensitive insulin secreting mesenchymal stem cells derived from human adipose tissue. *Indian J Endocr Metab* 2012;16:S65-9.
67. Ende N, Chen R, Reddi A. Transplantation of human human umbilical cord blood cells improves glycemia and glomerular hypertrophy in type 2 diabetic mice. *Biochem Biophys Res Commun* 2004;321:168-71.
68. Ende N, Chen R, Reddi A. Effects of human human umbilical cord blood cells on glycemia and insulinitis in type 1 diabetic mice. *Biochem Biophys Res Commun* 2004;325:665-9.
69. Urbán VS, Kiss J, Kovács J, Gócza E, Vas V, Monostori E, *et al.* Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. *Stem Cells* 2008;26:244-53.
70. Hess D, Li L, Martin M, Sakano S, Hill D, Strutt B, *et al.* Bone marrow-derived stem cells initiate pancreatic regeneration. *Nat Biotechnol* 2003;21:763-70.
71. Ezquer F, Ezquer M, Parrau D, Carpio D, Yahez A, Conget P. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycaemia and prevents nephropathy in type 1 diabetic mice. *Biol Blood Marrow Transplant* 2008;14:631-40.
72. Mahmoud A, Zuhair AB, Khaled RA, Sami AA, Abdelkarim SA, Iyad AA, *et al.* A preliminary study of the use of human adipose tissue-derived stem cells for the treatment of streptozotocin-induced diabetes mellitus in a rat model. *Comp Clin Pathol* 2010;19:1-4.
73. Lin G, Wang G, Liu G, Yang LJ, Chang LJ, Lue TF, *et al.* Treatment of Type 1 Diabetes with Adipose Tissue-Derived Stem Cells Expressing Pancreatic Duodenal Homeobox1. *Stem Cells Dev* 2009;18:1399-406.
74. Chandra V, Muthyala S, Jaiswal A, Bellare J, Nair P, Bhonde R. Islet-Like Cell Aggregates Generated from Human Adipose Tissue Derived Stem Cells Ameliorate Experimental Diabetes in Mice. *PLoS one* 2011;6:e20615.
75. Kajiyama H, Hamazaki TS, Tokuhara M, Masui S, Okabayashi K, Ohnuma K, *et al.* Pd×1-transfected adipose tissue-derived stem cells differentiate into insulin-producing cells *in vivo* and reduce hyperglycemia in diabetic mice. *Int J Dev Biol* 2010;54:699-705.
76. Couri CE, Voltarelli JC. Stem cell therapy for type 1 diabetes mellitus: A review of recent clinical trials. *Diabetol Metab Syndr* 2009;1:19.
77. Starzl TE. The "Privileged" Liver and Hepatic Tolerogenicity. *Liver Transpl* 2001;7:918-20.
78. Trivedi HL, Vanikar AV, Thakker U, Firoze A, Dave SD, Patel CN, *et al.* Human adipose tissue-derived mesenchymal stem cells combined with hematopoietic stem cell transplantation synthesize insulin. *Transplant Proc* 2008;40:1135-9.
79. Vanikar AV, Dave SD, Thakkar UG, Trivedi HL. Co-transplantation of adipose tissue-derived insulin-secreting mesenchymal stem cells and hematopoietic stem cells: A novel therapy for insulin-dependent diabetes mellitus. *Stem Cells Int* 2010;2010:582382.

Source of Support: Nil. Conflict of Interest: None declared.